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Summary:
Objective: To determine whether a less-invasive approach to surgery for medically-refractory 
temporal lobe epilepsy is associated with lower health care costs and costs of lost productivity 
over time, compared to open surgery.
Methods: We compared direct medical costs and indirect productivity costs associated with 
treatment with stereotactic radiosurgery (SRS) or anterior temporal lobectomy (ATL) in the 
Radiosurgery vs. Open Surgery for Epilepsy (ROSE) Trial. Health care use was abstracted from 
hospital bills, the study database and diaries in which participants recorded health care use and 
time lost from work while seeking care. Costs of use were calculated using a Medicare-costing 
approach used in a prior study of the costs of ATL. Power of many analyses was limited by the 
sample size and data skewing.
Results: Combined treatment and follow-up costs (in thousands of US dollars) did not differ 
between SRS (n=20, mean $76.6, 95% CI 50.7 – 115.6) and ATL (n=18, mean $79.0, 95% CI 
60.09 – 103.8). Indirect costs also did not differ. More ATL than SRS participants were free of 
consciousness impairing seizures in each year of follow up (all p < .05). Costs declined following 
ATL (p = .005). Costs tended to increase over the first 18 months following SRS (p = .17) and 
declined thereafter (p = .06). This mostly reflected hospitalizations for SRS-related adverse events 
in the second year of follow-up.
Significance: Lower initial costs of SRS for medial temporal lobe epilepsy were largely offset 
by hospitalization costs related to adverse events later in the course of follow-up. Future studies of 
less-invasive alternatives to ATL will need to assess adverse events and major costs systematically 
and prospectively in order to understand the economic implications of adopting these technologies.
Keywords
radiosurgery; lobectomy; epilepsy; healthcare; costs
Introduction:
Surgery for epilepsy is highly effective in controlling seizures in carefully selected patients 
when medications have failed 1–3. The initial costs of evaluation and surgery are high, but 
successful surgery is associated with improved quality of life and lower health care costs 
over time 4–6. Therefore, surgery has been considered sufficiently cost-effective to justify 
broader use on economic grounds 6–9.
Stereotactic radio-surgery (SRS)10, 11 and laser interstitial thermal therapy (LITT)12 have 
been proposed as less-invasive alternatives to open surgery, since they may result in seizure 
control similar to that obtained with open surgery and may result in less morbidity. Seizure-
free rates following less-invasive approaches have approached rates after open surgery in 
patients with mesial temporal lobe epilepsy (MTLE) 11, 13. There is preliminary evidence 
for equivalent or reduced impact on some aspects of cognitive function 11, 14. Less-invasive 
approaches also may be less costly, since they may not require an extended hospital stay 
Langfitt et al. Page 2













and convalescent period and may be associated with fewer complications. Therefore, less-
invasive approaches have the potential to be as cost-effective as open surgery, if not more so.
Health care costs associated with less-invasive alternatives have not been described or 
compared with costs associated with open surgery. Here, we compare health care costs 
during the Radiosurgery or Open Surgery for Epilepsy (ROSE) trial, a single-blinded, 




The participants, treatment protocols, follow-up methods and results with respect to 
seizure control, adverse events, verbal memory and quality-of-life of the ROSE Trial 
have been described in detail previously15. Briefly, ROSE was a multicenter, randomized, 
non-inferiority trial designed to compare the effectiveness of SRS to ATL in treating 
medically-refractory unilateral MTLE. Persons eligible for ROSE had been determined 
to be candidates for ATL at one of 15 centers in the USA, UK and India. Institutional 
review boards at the treatment centers approved the study (https://clinicaltrials.gov/ct2/
show/NCT00860145). MTLE diagnosis had been established by video EEG monitoring, 
and concordant unilateral hippocampal sclerosis on magnetic resonance (MRI) without 
significant secondary lesions. All participants were at least 18 years old and had had at least 
three focal onset seizures with impairment of consciousness in the three months prior to 
enrollment, while on stable anticonvulsant regimens. Patients determined to be appropriate 
for ATL were randomized to ATL or SRS at the time of enrollment, stratified by center and 
by hemisphere of speech dominance. Over the next 36 months, participants were scheduled 
for face-to-face or telephone follow-up every three months with standardized assessment of 
medical, neuropsychological and psychiatric outcomes. The study protocol directed that all 
patients remain on stable doses of medications throughout the study period.
Due to lagging recruitment, enrollment in ROSE was halted after treating 58 of 200 planned 
participants, therefore limiting the power of most planned analyses. By the 36 month 
end-point, 16/31 (52%) SRS-treated patients had been in remission from consciousness-
impairing seizures for the previous year, compared to 21/27 (78%) of ATL-treated patients. 
Consistent with the delayed effect of SRS, 74% of SRS-treated patients were seizure-free 
for the final three months of the study, compared to 85% of the ATL-treated group. At 36 
months, there were no differences between the groups in verbal memory performance or 
quality of life.
Determining Health Care Use and Costs:
Analysis of health care use was limited to participants at the 12 US-based sites, since 
patterns of healthcare use and methods for determining costs are different in the UK 
and India. Costs of treatment and follow-up care were derived from several sources of 
information using a Medicare costing approach (see Technical Appendix). Inpatient use 
at the study site hospital (including ATL) was estimated from charges recorded on a 
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Medicare-mandated billing form (UB-04) for all admissions to the hospital where treatment 
was performed. Medication use was assessed by study coordinators at each visit, including 
formulation (generic vs. brand), dosage (for AEDs, steroids and psychiatric medications 
only) and the dates they were started and stopped. All other health care use was assessed via 
diaries. In the diary that participants used to track seizures for the primary outcome, each 
participant was also asked to record six different types of health care use and the dates on 
which they occurred. These were 1) outpatient visits to a health care provider, 2) inpatient 
admissions, 3) laboratory tests (e.g., AED blood levels), 4) other tests and procedures (e.g., 
EEG, MRI), 5) dental care and 6) emergency department visits. Diaries were reviewed by 
study coordinators at each visit. Participants were prompted to use personal calendars and 
other records to aid recall of any health care use since the prior study visit.
Information about the timing and nature of serious and non-serious adverse events (AE) 
was extracted from the study database. We included all AEs that were possibly, probably, 
or definitely treatment-related, because we assumed that the likelihood that participants 
would seek care for them would be unrelated to the independent safety monitor’s confidence 
that they were treatment-related. There was insufficient information to determine directly 
whether hospital admissions were AE-related. For the current analysis, a hospitalization was 
considered AE-related if the two events occurred within a week of each other or the date of 
hospitalization fell between the dates of onset and resolution of the AE. For AEs that did 
not resolve, a hospitalization was considered AE-related if it occurred within a month of AE 
onset.
Statistical Analyses: Our primary hypothesis was that SRS would be associated with 
lower overall direct medical and indirect costs over the course of treatment and follow-up. 
Secondary hypotheses were that the time course of changes in follow-up costs would 
differ between the arms (due to expected differences in the timing of seizure remission 
between the treatments) and that seizure remission would be associated with lower health 
care use over time. Differences between arms in direct and indirect costs over time were 
compared using generalized linear mixed models (GLMM) for repeated measures with 
normal distribution and log link.16 Similar models with Poisson distribution and log link 
were used for the analysis of the number of other medications used. For analyses of change 
in follow-up costs over time, seizure remission status during each period was included in 
these models as a time-varying covariate. The time-trend analysis was based on the ratio of 
the mean costs during the current 6 months over the mean costs of the preceding 6 months, 
i.e., the multiplicative effect on mean costs for every 6- month follow-up increment.
Ancillary analyses of rates of health care and medication use over the follow-up period were 
performed using linear mixed models (LMM) for repeated measures, with treatment arm and 
year of follow-up treated as categorical variables. An unstructured covariance matrix was 
used to account for the dependence of the within-subject observations. T-tests, chi-square or 
Fisher’s exact tests were used to compare participants in the two treatment arms in terms 
of baseline demographics, clinical characteristics, occurrence of treatment-related AEs and 
seizure outcome.
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Two participants, one in each arm, were lost to follow-up (after the 12-month visit for ATL, 
after the 24-month visit for SRS). In treatment comparisons of costs and rates of use, values 
in the missing periods were imputed as the median values for all other participants for those 
periods. In other analyses examining changes over time, the GLMMs and LMMs used all 
available data in parameter estimation.
Results:
Participants:
Of the 58 ROSE participants (31 SRS, 27 ATL) included in the analyses of the trial’s 
primary outcomes, 38 (20 SRS, 18 ATL) were treated at US-based sites and were included 
in the current analyses. Similar to the main ROSE sample, there were no statistically 
significant differences between treatment groups in age at surgery, gender distribution, 
epilepsy duration, number of AEDs, or total number of all medications taken at enrollment 
(Table 1). SRS participants tended to have a higher monthly seizure frequency at enrollment 
(p = .06). More participants in the ATL arm were free of consciousness impairing seizures in 
each of the three years of follow-up (all p < .05) (Table 2).
Total Direct and Indirect Medical Costs:
Combined treatment and follow-up costs did not differ significantly between treatment 
arms. ATL was associated with an estimated mean direct medical cost per-participant (in 
thousands of dollars) of 78.98 (95% CI = 50.72 – 115.60), compared to 76.57 (95% CI = 
60.09 – 103.82) for SRS (p > .10). Combined direct and indirect costs also did not differ 
across arms (ATL = 154.9 (95% CI = 122.9 – 195.4) vs. SRS = 167.9 (95% CI = 134.0 – 
210.2, p > .10).
Changes in Costs during Follow-up:
In regression analyses, ATL- and SRS-treated groups differed significantly in the ratio of 
mean direct medical costs over the last six months to those of the first six months of 
follow-up (ATL = 0.58 (95% CI 0.40–0.85), SRS = 1.02 (95%CI 0.72 – 1.45), p =.03). 
For the time-trend analyses, in the ATL group, every 6 months of follow-up was associated 
on average with an approximately 11% decrease in mean direct medical costs (0.89 (95% 
CI 0.83–0.97), p = .005). In the SRS arm, mean costs tended to increase over the first 18 
months of follow-up (1.15 (95% CI 0.94–1.40), p =.17) and then tended to decrease over the 
remaining 18 months (0.90 (95% CI 0.80–1.01), p = .06). Changes in mean costs over time 
were not associated with concurrent seizure remission status in either arm (both p > .20). 
Mean costs for each 6-month period estimated from the regression model are shown in Table 
2. Hospitalizations, AEDs and psychiatric medications accounted for > 90% of follow-up 
costs across all periods (see Table 3). Costs of AEDs did not differ between treatments 
or across time and were not associated with remission status (all p > .10). Analyses of 
differences in costs between ATL and SRS for other types of utilization were precluded by 
the small sample size and skewed nature of cost data.
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Treatment Differences in Rates of Use of Different Types:
The trends noted above were explored by examining rates of use between arms by year 
of follow-up, since the distribution of rates of use was less skewed than the distribution 
of costs. The rate of health care use of all types increased over time in the SRS arm 
and declined in the ATL arm (Treatment x Time interaction p = .04) (Table 4). This was 
attributable to a decline over time in hospitalizations and laboratory tests following ATL, 
relative to SRS (p < .05). Rates of use were not associated with seizure remission status, 
except that participants in remission were less likely to visit the emergency department (p 
= .03). Change in the number of AEDs used over time tended to differ, with use declining 
after ATL, relative to SRS (Treatment x Time p = .08), despite the fact that the protocol 
advised maintaining participants on their pre-treatment AED regimen throughout followup. 
Participants in the SRS arm used more psychiatric and non-AED medications consistently 
across all periods (p < 0.03 at each period). Both groups increased their use of other 
medications over the course of follow-up (both p < .02). Use of other medications was not 
associated with seizure remission (both p > .20).
Adverse Events and their Association with Costs: One ATL participant 
experienced a serious AE (wound dehiscence) compared to seven SRS participants (p < 
.05), who experienced eight serious AEs between 7 and 24 months of follow-up (increased 
headaches (n=3), cerebral edema (n=2), status epilepticus (n=1), increased seizures (n=1), 
new neurologic deficit (n=1). All serious AEs were associated with hospitalization. 
Seventeen SRS participants experienced non-serious AEs compared to six ATL participants 
(p < .01). SRS participants experienced a total of 61 non-serious AEs, most of which 
were less severe increases in cerebral edema, headaches or seizures, mood or cognitive 
changes or self-limited neurologic deficits. ATL participants experienced 11 non-serious 
AEs (decline in memory (n= 5), subdural hematoma (n=2), increase in seizures (n=1), new 
onset headaches (n=1), double vision (n=1) and hyponatremia (n=1).
Figure 1 depicts the range of treatment and per-participant direct medical costs (excluding 
medications) across the follow-up period. Within each arm, participants varied widely in 
their health care use, as reflected in the large standard deviations (relative to means) 
in total direct costs and in rates of use. Most periods of high use were associated 
with hospitalizations and occurrence of AEs, particularly following SRS. Across both 
treatments, experiencing a serious AE was associated with higher total follow-up costs 
(excluding AEDs) (r= 0.45, p < .01), but experiencing a non-serious AE was not (r= 
0.19, p > .10). Ten SRS participants had a total of 21 hospitalizations, compared to a 
total of four hospitalizations in two ATL participants (p < .05). Within the SRS arm, 
all serious AEs and most hospitalizations occurred between the 6 and 18 month visits, 
corresponding to the period of maximum effect of radiation-induced cerebral edema, with 
associated increase in headaches or non-consciousness impairing seizures 11. Twelve of 
the 14 (86%) hospitalizations during this time were AE-related, compared to 2 of the 7 
(29%) hospitalizations during other periods (p < .05). Only one of the four hospitalizations 
after ATL was AE-related (wound dehiscence). The per-participant, mean combined costs 
of initial treatment, follow-up hospitalizations and emergency treatment were roughly 
equivalent between the two arms (see Figure 2). This reflects the fact that the lower initial 
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treatment costs of SRS were offset by higher costs associated with more frequent, serious, 
treatment-related AEs, many of which led to hospitalization.
Discussion:
Contrary to our hypothesis, we failed to demonstrate lower direct medical costs associated 
with SRS compared to ATL over the course of the trial. It is possible that we were unable to 
detect a small but meaningful relative costs savings of SRS, because of the relatively small 
sample size and the skewed nature of health care cost data. On the other hand, SRS had 
two distinct disadvantages in this study that likely contributed to the absence of an expected 
cost-savings effect.
The first disadvantage was that SRS participants were more likely to experience treatment-
related AEs that led to hospitalization. Hospitalization was far and away the most costly 
type of follow-up care. As shown in Figure 2, the cost of these hospitalizations effectively 
eliminated the relative economic benefit of the lower initial treatment costs of SRS. This 
suggests that the ultimate cost-effectiveness of less invasive alternatives to open surgery for 
epilepsy depends on their achieving similar rates of seizure freedom to ATL, as well as 
similar or lower rates of post-operative adverse events and hospitalizations.
Adverse events and hospitalizations have not always been assessed and reported consistently 
in studies of epilepsy surgery. ATL case series have reported relatively low (~5%) post-
operative complication rates 17, with higher rates (10–33%) reported in randomized trials 
1, 2. In a retrospective medical record review of a subset of 68 patients enrolled in a large 
prospective, observational study of epilepsy surgery, there were 0.04 hospitalizations per 
patient-year in patients who were seizure-free after ATL, compared to 0.25 hospitalizations 
per patient-year among surgical and non-surgical patients with persistent seizures 5. In a 
recent meta-analysis, the pooled estimate of seizure-free outcome after SRS was 51% (95% 
CI 38–64%)18. The most common adverse event was headache, which occurred in 9–85% 
of series in which it was reported (median 43%). The meta-analysis did not address severity 
and consequences of headaches, but headaches led to hospitalization in 20% of our sample 
who reported them. In our experience, the presence of transient SRS-associated cerebral 
edema rather than the severity of headache is typically the driver for inpatient evaluation. 
Some hospitalizations therefore could have arisen because of center-to-center differences in 
comfort with the management of this expected result of focal radiation 11. ATL has been 
used in the treatment of refractory epilepsy for decades and most treatment teams are very 
comfortable with post-operative and long-term management. This may not be the case for 
newer procedures, such as SRS. Patients treated with SRS for neoplasms are managed by 
neurosurgeons and radiation oncologists with considerable experience with these diagnoses 
and treatments. In the ROSE Trial, neurosurgeons and radiation oncologists performed all 
of the SRS procedures, but the medical management over time was typically provided by 
neurologists. It is possible that long-term costs of care would decrease as clinicians become 
more experienced in outpatient management of post-radiation side effects.
Case series of LITT for mesial temporal lobe epilepsy with MTS have reported seizure-free 
rates ranging from 36–80% 12. LITT typically requires shorter hospital stays than ATL 
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and patients frequently enter seizure remission immediately after the procedure, so one 
might predict that overall costs of care would be less than with ATL or SRS. However, 
rates of adverse events range from 4–28% in series where they have been reported. Several 
of these (hemorrhage, infarcts, atrial fibrillation, cranial nerve injuries) may have merited 
hospitalization. Initial LITT failure may lead to additional procedures or to ATL 13, 19, costly 
interventions that must be included in overall cost estimates of this approach.
The second disadvantage of SRS was that fewer SRS-treated participants achieved one-
year seizure remission than was expected, based on results of the pilot study 11. Seizure-
freedom has been reliably associated with lower costs in most studies of epilepsy samples, 
including following ATL 5, 6, 20, 21. Consistent with this observation, the majority of ATL-
treated participants entered remission early and follow-up costs declined over time. Seizure 
remission was not statistically associated with follow-up costs in the per-period analyses. 
Our ability to detect this association within groups and over time may have been limited 
by the large difference between groups in rates of seizure-freedom and the outsized impact 
on costs of hospitalizations in the SRS arm for adverse events unrelated to seizure control. 
Reductions in health care use after ATL also lag achievement of seizure freedom by up to a 
year 5, 6, presumably because patients and providers are waiting to see whether initial results 
are reliable. Finally, protocol-averted costs may have led us to underestimate the difference 
in outpatient follow-up costs associated with remission. Were it not for the prescribed study 
visits, participants with ongoing seizures likely would have sought care for their seizures 
elsewhere, whereas patients in remission may have done so less often.
There are several other limitations to these results. We only followed participants for 3 years. 
Differences in long-term costs might persist or attenuate to the degree that rates of seizure-
freedom and adverse events following SRS may converge toward, or remain distinct from 
those after ATL. Longer-term observation is required. Use of a health care diary may have 
introduced some error into the assessment of utilization during follow up, but it is unlikely 
to have biased treatment comparisons substantially. Health utilization diaries provide a 
generally valid assessment of utilization ( Leggett, L. E., Khadaroo, R. G., Holroyd-Leduc, 
J., Lorenzetti, D. L., Hanson, H., Wagg, A., … Clement, F. (2016). Measuring Resource 
Utilization: A Systematic Review of Validated Self-Reported Questionnaires. Medicine, 
95(10), e2759.), particularly for hospitalizations, which accounted for the major differences 
in follow-up costs between treatments. Excluding inpatient utilization, costs estimated from 
diaries were < 10% of total costs associated with either treatment. Larger treatment and 
medication costs were estimated from medical record and administrative data. There is no 
reason to believe that randomized participants would have provided biased estimates of 
utilization in their diaries. Finally, validity of the diary in this study is supported by the 
observations that a) the timing of hospitalizations recorded in the diaries by SRS participants 
corresponded to the peak incidence of adverse events and radiation-induced edema and b) 
changes in utilization associated with seizure freedom following ATL followed a similar 
time course reported in prior studies. The indirect costs that we assessed were incomplete. 
They were selected based on considerations of feasibility, likely effect size, and likelihood of 
their being affected by treatment outcomes. Seizures can reduce productivity (e.g., decreased 
efficiency if recovering from seizures, reduced career trajectory), but effects can also be 
mitigated (e.g., by improved work output to cover for lost time). Accounting for these 
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effects would require assessment methods (e.g., employment records, time and motion 
studies, long-term employment outcomes) that are not feasible to obtain in the context 
of a multisite randomized controlled trial where costs were not the primary outcome. We 
focused on participants’ employment status and caregivers’ lost work hours, since lost work 
productivity is arguably the largest category of costs in this population, given the high rates 
of unemployment in this population and the high unit cost. Costs associated with under- and 
unemployment have also been the primary focus of estimates of the indirect cost of epilepsy 
in prior studies (Begley et al. 2000).
In conclusion, combined treatment and follow-up costs associated with ATL and SRS appear 
to be comparable. As in prior studies, costs declined after ATL which rendered most patients 
free of seizures, but at a higher initial treatment cost. Costs following SRS remained largely 
stable, with a tendency to increase in the second year and then decline, associated with 
maximal radiation effect, serious adverse events and associated hospitalizations. The costs 
associated with these hospitalizations and other care effectively eliminated the cost-savings 
associated with the less-expensive SRS treatment. In order to fully evaluate the economic 
implications of adopting less-invasive alternatives to ATL, future studies will need to assess 
adverse events and major costs systematically and prospectively over the time periods in 
which they can be expected to occur.
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1. Less-invasive approaches to epilepsy surgery may control seizures as well as 
open surgery, but with potentially lower morbidity and cost.
2. In a randomized trial comparing radiosurgery to temporal lobectomy, total 
costs were comparable over the course of the three-year trial.
3. The lower initial cost of radiosurgery was offset by higher follow-up costs 
associated with adverse events and hospitalizations.
4. Future studies of less-invasive approaches should track costs carefully to fully 
understand the economic implications of their use.
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Treatment cost ranges and direct medical costs (excluding AEDs) across follow-up for 
each study participant, by arm. Blue-to-red shading within cells represents increasing cost. 
Numbers on the left half of each cell are the number of serious AEs (to the left of the “/” 
mark) and non-serious AEs (to the right of the “/” mark) experienced during the period. 
Numbers on the right half of each cell are the total number of hospitalizations (to the left of 
the mark) and AE-related hospitalizations (to the right of the mark) experienced during the 
period.
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Mean, per-participant total treatment and follow-up direct medical costs (in thousands) 
between SRS and ATL, by type of cost.
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TABLE 1 –
Demographics at Randomization
SRS (n=20) ATL (n=18) p
Gender (% female) 60 39 ns
Age at Diagnosis (yrs) 19.0 (17.3) 12.1 (12.4) ns
Age at Surgery (yrs) 44.5 (11.2) 45.9 (10.7) ns
Epilepsy Duration (yrs) 25.5 (16.0) 33.8 (13.8) ns
AEDs (n) 2.4 (1.2) 2.5 (2.0) ns
Total Medications (n) 5.5 (3.0) 4.3 (3.2) ns
Monthly Seizure Frequency (n) 6.9 (7.3) 3.4 (2.4) .06
Numbers in cells are means and standard deviations.
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TABLE 2 –




1–6 7–12 13–18 19–24 25–30 31–36
Direct Medical Costs
ATL 23.6 (18.9–28.3) 12.7 (8.9–18.2) 9.0 (6.0–13.4) 9.8 (6.2–15.5) 7.7 (4.9–12.1) 7.7 (5.0–11.8) 7.4 (4.7–11.6)
SRS 11.6 (N/A) 10.0 (5.8–17.1) 11.4 (7.5–17.3) 14.2 (8.3–21.2) 10.0 (6–16.7) 10.8 (6.2–18.9) 10.2 (5.8–17.9)
Indirect Costs of Lost Employment and Work Hours














Free of Consciousness Impairing Seizures in Past Year (%)
ATL 0 78 78 78
SRS 0 5 0 35
Numbers in cells are means and 95% CI’s. The CI for SRS treatment cost is undefined, since the cost of SRS was estimated as the Medicare 
reimbursement which did not differ across sites and participants (see Technical Appendix).
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TABLE 3 –
Mean Annual Cost ($1000s) by Type of Use (excluding study visits)
ATL SRS
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Outpatient Visits 0.4 (0.8) 0.2 (0.3) 0.2 (0.2) 0.3 (0.3) 0.3 (0.3) 0.4 (0.4)
Hospitalizations 1.4 (4.2) 0.0 (0.0) 0.5 (1.9) 2.9 (7.7) 3.7 (6.8) 1.2 (3.0)
Laboratory Tests 0.03 (0.1) 0.01 (0.01) 0.01 (0.02) 0.01 (0.02) 0.03 (0.1) 0.02 (0.04)
Other Tests/Procedures 0.3 (0.4) 0.2 (0.4) 0.2 (0.3) 0.3 (0.4) 0.3 (0.3) 0.5 (0.7)
Dental Care 0.1 (0.2) 0.1 (0.2) 0.1 (0.2) 0.01 (0.03) 0.1 (0.2) 0.03 (0.1)
Emergency Care 0.02 (0.1) 0.01 (0.05) 0.0 (0.0) 0.1 (0.2) 0.1 (0.2) 0.1 (0.2)
AEDs 17.9 (15.2) 15.9 (15.6) 12.9 (14.3) 15.8 (19.4) 16.4 (23.6) 15.8 (25.3)
Psychiatric Meds 1.65 (4.5) 1.2 (2.6) 1.4 (3.4) 1.4 (2.5) 1.2 (2.0) 0.6 (1.2)
Numbers in cells are means and standard deviations
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TABLE 4 –
Mean Annual Number of Use Episodes and Medications Prescribed (excluding study visits)
ATL SRS
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Healthcare Use (n) 9.9 (13.1) 6.6 (8.0) 5.0 (3.6) 6.9 (6.2) 7.8 (7.2) 9.8 (7.8)
Outpatient Visits 4.6 (10.0) 2.4 (3.3) 2.4 (2.2) 3.1 (3.9) 3.0 (3.3) 4.7 (4.5)
Hospitalizations 0.2 (0.5) 0.0 (0) 0.1 (0.2) 0.3 (0.9) 0.4 (0.8) 0.1 (0.4)
Laboratory Tests 0.8 (1.7) 0.2 (0.4) 0.1 (0.5) 0.3 (0.7) 0.8 (1.6) 0.5 (1.0)
Other Tests/Procedures 1.1 (1.5) 0.8 (1.4) 0.8 (1.1) 1.1 (1.6) 0.9 (1.1) 1.8 (2.5)
Dental Care 0.6 (1.5) 0.5 (1.7) 0.5 (1.2) 0.05 (0.2) 0.5 (1.6) 0.2 (0.6)
Emergency Care 0.1 (0.5) 0.1 (0.2) 0.0 (0) 0.6 (0.2) 0.6 (1.2) 0.5 (0.9)
Medication Use (n)
AEDS 2.4 (1.1) 2.4 (1.1) 2.3 (1.1) 2.5 (1.1) 2.6 (1.0) 2.7 (1.1)
Psychiatric 0.6 (0.8) 0.5 (0.8) 0.6 (0.9) 0.7 (.8) 0.8 (0.9) 0.5 (0.7)
Other 1.2 (0.9) 1.4 (1.2) 1.6 (1.8) 2.8 (2.9) 3.7 (4.3) 4.2 (5.2)
Numbers in cells are means and standard deviations
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